ALDR stock news

Alder BioPharmaceuticals (ALDR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 16) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR )( announced a deal to be bought by Danish pharma company Lundbeck) AxsomeTherapeutics Inc (NASDAQ: AXSM ) Kodiak Sciences Inc (NASDAQ: KOD )(announced positive emerging durability data from a Phase 1b study of its pipeline asset KSI-301 in wet age-related macular degeneration) The Medicines Company (NASDAQ: MDCO ) Natera Inc (NASDAQ: NTRA ) -mAbs Therapeutics, Inc (NASDAQ: YMAB ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Down In The Dumps (Biotech stocks hitting 52-week lows on Sept. 16) BioNano Genomics Inc (NASDAQ: BNGO ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) Helius Medical Technologies Inc (NASDAQ: HSDT ) Myovant Sciences Ltd (NYSE: MYOV ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Viveve Medical Inc (NASDAQ: VIVE ) Stocks In Focus Acceleron To Discontinue Development Of Mid-Stage Asset To Treat Muscular Dystrophy Acceleron Pharma Inc (NASDAQ: XLRN ) said it's halting the development of ACE-083 as a treatment option for patients with facioscapulohumeral muscular dystrophy. Read more
Merger Monday dawned with Danish pharma company Lundbeck announcing a definitive agreement to buy U.S.-based Alder Biopharmaceuticals Inc (NASDAQ: ALDR ). The Deal Terms Alder shareholders will receive $18 per share in cash as part of the deal, along with one tradeable contingent value right that entitles them to receive an additional $2 per share upon approval of eptinezumab — a Phase 3 migraine prevention drug candidate — by the European Medicines Agency. This renders the total consideration to $20 per share, with a total transaction value of $1.95 billion net of cash on a fully diluted basis. The upfront cash payment of $18 per share represents a 79% premium to the Sept. 13 closing price of Alder shares . The boards of both companies have approved the transaction. The proposed deal is expected to close in the fourth quarter of 2019, subject to customary closing conditions, including tendering of more than 50% of Alder shares at … Full story available on Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 27) Castle Biosciences Inc (NASDAQ: CSTL ) The Medicines Company (NASDAQ: MDCO ) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 27) Abeona Therapeutics Inc (NASDAQ: ABEO ) Advaxis, Inc. (NASDAQ: ADXS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alimera Sciences Inc (NASDAQ: ALIM ) AnaptysBio Inc (NASDAQ: ANAB ) ASLAN PHARMACEU/ADR (NASDAQ: ASLN ) Assembly Biosciences Inc (NASDAQ: ASMB ) Cancer Genetics Inc (NASDAQ: CGIX ) Catalyst Biosciences Inc (NASDAQ: CBIO ) Clearside Biomedical Inc (NASDAQ: CLSD ) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI )(announced that its current cash position will be sufficient to complete enrollment in all three patient groups of its two ongoing Phase 2 trials for its lead compound VAL-083, which is likely to occur by the fourth quarter of 2020) ICU Medical, Incorporated (NASDAQ: ICUI ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Mallinckrodt PLC (NYSE: MNK )(reacted to an unfavorable ruling on a patent infringement lawsuit regarding its inhaled nitric oxide product) Neuralstem, Inc. (NASDAQ: CUR ) Novus Therapeutics Inc (NASDAQ: NVUS ) Obalon Therapeutics Inc (NASDAQ: OBLN ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Regenxbio Inc (NASDAQ: RGNX ) Revance Therapeutics Inc (NASDAQ: RVNC )(announced an amended agreement with Mylan NV (NASDAQ: MYL ), … Read more
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks No biotech stocks hit 52-week highs Monday. Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 5) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Actinium Pharmaceuticals Inc (NYSE: ATNM ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Akcea Therapeutics Inc (NASDAQ: AKCA )(announced its subsidiary Keryx Biopharmaceuticals has reached a settlement agreement with Endo International PLC (NASDAQ: ENDP )'s Par Pharam related to Auryxia) Akebia Therapeutics Inc (NASDAQ: AKBA ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ) Amneal Pharmaceuticals Inc (NYSE: AMRX )( reported below-consensus Q2 results and cut its 2019 guidance) AnaptysBio Inc (NASDAQ: ANAB ) Arcus Biosciences Inc (NYSE: RCUS ) Assertio Therapeutics Inc (NASDAQ: ASRT ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) Atreca Inc (NASDAQ: BCEL ) Cellectis SA (NASDAQ: CLLS ) Champions Oncology Inc (NASDAQ: CSBR ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX )(commenced Phase 2 study of ELX-02 in cystinosis) Endo International Enochian Biosciences Inc (NASDAQ: ENOB ) ESSA Pharma Inc (NASDAQ: EPIX ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD )(reacted to Q2 results) GENFIT S A/ADR (NASDAQ: GNFT ) GlycoMimetics Inc (NASDAQ: GLYC )(reported that Phase 3 trial evaluating sickle cell disease drug it is co-developing with Pfizer Inc. Read more
Alder Biopharmaceuticals, Inc. (ALDR) has been struggling lately, but the selling pressure may be coming to an end soon. Read more
- Data presented at the 2019 American Academy of Neurology (AAN) meeting demonstrate nearly 60% of patients reported very much or much improvement in most bothersome symptoms and in overall migraine status following two treatments with eptinezumab - - Study represents first time most bothersome symptom data has been reported in a chronic migraine prevention study - BOTHELL, Wash., May 08, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR ), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced a new analysis of patient-reported outcomes data from the PROMISE-2 Phase 3 clinical trial of eptinezumab for the prevention of chronic migraine. Eptinezumab is an investigational monoclonal antibody (mAb) targeting the calcitonin gene-related peptide (CGRP) administered by quarterly infusion for migraine prevention. The new analysis showed improvements in most bothersome migraine symptoms and patients' global impression of change in their migraine status by Month 1 after treatment, with improvements sustained or increased through the first and second quarterly infusion. Read more
ALDR earnings call for the period ending March 31, 2019. Read more
Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) Q1 2019 Earnings Conference Call May 02, 2019, 17:00 ET Company Participants Michael Horowicz - Stern Investor Rela Read more
BOTHELL, Wash., April 22, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR ), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for eptinezumab. Eptinezumab is an investigational monoclonal antibody (mAb), administered intravenously, for migraine prevention targeting the calcitonin gene-related peptide (CGRP) and is Alder's lead commercial candidate. The company submitted its BLA on February 21, 2019 and continues to expect to receive a Prescription Drug User Fee Act (PDUFA) action date within 74 days following the submission. If the FDA grants approval of eptinezumab, Alder anticipates a Q1 2020 commercial launch. "Migraine is far more than a headache, it's a serious neurological disease with a debilitating impact to patients that can lead to other issues including depression, anxiety, and sleep disturbances," said Bob Azelby, Alder's president and chief executive officer. "The FDA's acceptance of our BLA is an important milestone, and the company remains focused on supporting the application review for the first quarterly infusion therapy for patients suffering from episodic and chronic migraine. Read more
Jim Cramer chats with Alder Biopharmaceuticals CEO Robert Azelby to find out what the company is doing to address chronic migraine. Read more
Both Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) and Acceleron Pharma Inc. (NASDAQ:XLRN) are each other’s competitor in the Biotechnology industry. Thus the contrast of their risk, analyst recommend Read more
In trying to determine the current valuation of Alder BioPharmaceuticals, Inc. (NasdaqGM:ALDR) shares, we note that the Book to Market ratio of the shares stands at 0.096896. It’s commonly accepted Read more
Investors might be trying to gauge which way shares of Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) will swing over the next couple of quarters. In recent trading activity, the stock has been seen nea Read more
This is therefore a contrasting of the risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation in Alder Read more

Proudly made at